The TTM and ASM Trial
Key facts
- Who runs it
- National Taiwan University Hospital
- Where
- Taiwan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 100 people, planned
- Started
- 17 Sept 2026
- Expected to end
- 31 Jul 2029
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Prophylactic ASM
- Hypothermic
- Normothermic
- ASM as needed
- Record updated
- 7 October 2026
Who can take part
- Age
- 18 years to 99 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Non-traumatic sudden cardiac arrest in adults
- Sustained return of spontaneous circulation (ROSC) for at least 5 minutes
- Admitted to the intensive care unit (ICU), remaining comatose and unable to follow commands
- TIMECARD score indicating moderate-to-severe illness severity
- Randomization and initiation of the intervention can be completed within 12 hours after ROSC
Who cannot take part
- Patients with terminal cancer or cancer for which active treatment has been declined
- Spontaneous hypothermia with a body temperature < 35°C; intracranial hemorrhage or massive bleeding
- Age < 18 years; pregnant or breastfeeding women
- TIMECARD score indicating mild risk
- Pre-arrest Cerebral Performance Category (CPC) score of 3-4; receipt of extracorporeal cardiopulmonary resuscitation (ECPR; CPR with ECMO)
- Refusal of participation by the patient's family
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Sudden cardiac arrest (SCA) remains one of the major challenges in clinical care.
Read full original descriptionShow less
Although improvements in resuscitation quality have increased the likelihood of return of spontaneous circulation (ROSC), most patients still fail to survive to hospital discharge, and neurological injury is the leading determinant of poor outcome. Hypoxic-ischemic encephalopathy caused by global cerebral hypoxia during cardiac arrest is a key contributor to long-term disability, and even survivors often experience substantial functional impairment, placing a significant burden on families and society. Targeted temperature management (TTM) has long been regarded as a cornerstone neuroprotective strategy; however, TTM and TTM2 trials reported no significant neurological difference between lower and higher temperature targets. However, these studies predominantly enrolled patients with relatively mild illness severity, and multiple real-world observational cohorts suggest that, among more severely ill resuscitated patients, lower target temperatures may still confer benefit. Consequently, the optimal temperature strategy in higher-risk subgroups remains uncertain. Seizures are another common manifestation of brain injury after cardiac arrest, occurring in approximately 20-30% of resuscitated patients and contributing to secondary neurological damage. Earlier trials evaluating prophylactic anti-seizure medication (ASM) (thiopental or diazepam/magnesium) did not demonstrate neurological benefit; however, these studies primarily focused on neuroprotection rather than seizure prevention, leaving a substantial evidence gap. Patients with moderate to severe disease severity-those at the highest risk of both cerebral injury and seizure occurrence-have never been specifically studied to determine whether personalized temperature selection or early short-term prophylactic ASM (e.g., valproic acid or levetiracetam) may provide clinical benefit. Accordingly, identifying the most appropriate temperature target for higher-risk patients and determining whether short-term prophylactic antiepileptic therapy can reduce seizure-related injury represent important unresolved questions in post-resuscitation care. The aim of this study is to conduct a prospective, multicenter, randomized clinical trial to evaluate whether, among comatose patients with moderate to severe risk after ROSC, specific TTM temperature strategies combined with early short-term prophylactic ASM can reduce postresuscitation seizure incidence and improve neurological outcomes. By addressing a population underrepresented in prior clinical trials-those at highest risk and most likely to benefit-this study aims to generate clinically meaningful evidence to guide temperature selection and prophylactic ASM after cardiac arrest. Evaluating these interventions in combination may provide a more comprehensive understanding of whether they reduce seizure burden, mitigate brain injury, and improve functional recovery.
The 4 groups in the trial
- Hypothermic PPXTreatment being tested
hypothermia + Prophylactic treatment
Treatment: Prophylactic ASM and Hypothermic
- Normothermic PPXExisting treatment, for comparison
Normothermic + Prophylactic treatment
Treatment: Prophylactic ASM and Normothermic
- Hypothermic PRNExisting treatment, for comparison
hypothermia + as needed
Treatment: Hypothermic and ASM as needed
- Normothermic PRNExisting treatment, for comparison
Normothermic + as needed
Treatment: Normothermic and ASM as needed
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Optimization of Neurological and Functional Recovery Following Cardiac Arrest
- Criteria questions
- Built from NCT07835802, who can take part
- Record updated
- 7 October 2026